Pfizer Inc. (NYSE:PFE) Position Boosted by Nomura Holdings Inc.

Nomura Holdings Inc. increased its position in shares of Pfizer Inc. (NYSE:PFE) by 1,854.2% during the fourth quarter, Holdings Channel reports. The institutional investor owned 529,323 shares of the biopharmaceutical company’s stock after purchasing an additional 502,237 shares during the period. Nomura Holdings Inc.’s holdings in Pfizer were worth $22,956,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. Advocacy Wealth Management Services LLC increased its holdings in shares of Pfizer by 48.2% in the fourth quarter. Advocacy Wealth Management Services LLC now owns 793 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 258 shares during the last quarter. Winch Advisory Services LLC increased its holdings in shares of Pfizer by 69.6% in the fourth quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 336 shares during the last quarter. 1 North Wealth Services LLC acquired a new position in shares of Pfizer in the fourth quarter valued at $40,000. Ruggie Capital Group acquired a new position in shares of Pfizer in the fourth quarter valued at $44,000. Finally, Contravisory Investment Management Inc. increased its holdings in shares of Pfizer by 182.6% in the fourth quarter. Contravisory Investment Management Inc. now owns 1,153 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 745 shares during the last quarter. Institutional investors and hedge funds own 71.88% of the company’s stock.

In related news, insider Rady A. Johnson sold 8,700 shares of the company’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $41.13, for a total transaction of $357,831.00. Following the completion of the sale, the insider now owns 59,797 shares of the company’s stock, valued at $2,459,450.61. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Pfizer Inc acquired 50,000 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The shares were purchased at an average cost of $17.00 per share, with a total value of $850,000.00. The disclosure for this purchase can be found here. Insiders own 0.09% of the company’s stock.

Shares of Pfizer stock opened at $43.08 on Thursday. The stock has a market capitalization of $237.24 billion, a PE ratio of 14.36, a price-to-earnings-growth ratio of 2.46 and a beta of 0.65. Pfizer Inc. has a 52-week low of $35.73 and a 52-week high of $46.47. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.54 and a quick ratio of 1.27.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, April 30th. The biopharmaceutical company reported $0.85 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.10. The company had revenue of $13.12 billion during the quarter, compared to analysts’ expectations of $13.01 billion. Pfizer had a net margin of 21.31% and a return on equity of 27.48%. Pfizer’s quarterly revenue was up 1.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.77 earnings per share. As a group, analysts anticipate that Pfizer Inc. will post 2.89 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, June 7th. Stockholders of record on Friday, May 10th were given a $0.36 dividend. The ex-dividend date was Thursday, May 9th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.34%. Pfizer’s payout ratio is presently 48.00%.

PFE has been the topic of several research reports. Zacks Investment Research downgraded shares of Pfizer from a “hold” rating to a “sell” rating in a report on Thursday, March 28th. Cantor Fitzgerald reiterated a “buy” rating and issued a $53.00 price objective on shares of Pfizer in a report on Tuesday, February 19th. Citigroup reiterated a “neutral” rating and issued a $41.00 price objective on shares of Pfizer in a report on Wednesday, February 20th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $46.00 price objective on shares of Pfizer in a report on Friday, April 19th. Finally, Bank of America upped their price objective on shares of Pfizer from $45.00 to $48.00 and gave the company a “buy” rating in a report on Monday, April 1st. Thirteen investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $46.00.

TRADEMARK VIOLATION NOTICE: “Pfizer Inc. (NYSE:PFE) Position Boosted by Nomura Holdings Inc.” was first posted by Modern Readers and is owned by of Modern Readers. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.modernreaders.com/news/2019/06/13/pfizer-inc-nysepfe-position-boosted-by-nomura-holdings-inc.html.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: Straddles

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.